

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY G
04 MAR 29

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Steven Giuli			
2. Address <input type="checkbox"/> Check if different than previously reported 1725 1st, NW Ste 300			
3. Principal Place of Business (if different from line 2) City: Washington State/zip (or Country) DC 20006			
4. Contact Name Steve Giuli		Telephone	E-mail (optional)
7. Client Name <input type="checkbox"/> Self Alpharma US Human Pharmaceuticals			5. Senate ID # 89190
			6. House ID #

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇔ Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇔ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇔ \$ <u>72,500</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature: Steven Giuli Date: 2/13/04

Printed Name and Title STEVEN CIVIL, Director of Legislative Affairs

LD-2 (REV. 4/03)

PAGE 1 of -

Registrant Name Steven Giuli Client Name Alpharma, US Human Pharmacol

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code _____ (one per page) MMM, TAX, PHA, LBR

16. Specific lobbying issues

See attached sheets.

17. House(s) of Congress and Federal agencies contacted Check if None

US House of Representatives
US Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steve Giuli</u>	<u>Leg. Director, Cong. Frank Pallone, Jr.</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Steven Giuli Date 2/13/04

Printed Name and Title Steven Giuli, Director of Legislative Affairs

MMM

1. S. 1225, the Greater Access to Affordable Pharmaceuticals Act
2. S.1, Prescription Drug and Medicare Improvement Act
 - a. Title VII, Access to Affordable Pharmaceuticals
 - b. Title VIII, Importation of Prescription Drugs
 - c. Title IX, Drug Competition Act of 2003
3. HR 1, Medicare Prescription Drug and Modernization Act of 2003
 - a. Title XI, Access to Affordable Pharmaceuticals, Subtitles a, Access to Affordable Pharmaceuticals, b, Federal Trade Commission Reviews and, c, Importation of Prescription Drugs

TAX

1. S. 596, the Invest in the USA Act
2. S 1637, Jumpstart Our Business Through Strength Act
 - a. Section 231, Toll Tax on Excess Qualified Foreign Distribution Amount
3. HR 767, the Homeland Investment Act



PHA

1. HR 2427, The Pharmaceutical Marketing and Access Act of 2003

LBR

1. S.1, Prescription Drug and Medicare Improvement Act
 - a. Title IX, Drug Competition Act of 2003
2. HR 1, Medicare Prescription Drug and Modernization Act of 2003
 - a. Subtitle b, Federal Trade Commission Review

